Immunic, Inc. Reveals Conference Participation for May Events
Immunic, Inc. Announces Participation in Upcoming Conferences
Immunic, Inc. (Nasdaq: IMUX), an innovative biotechnology company, is gearing up for an exciting month of May as it participates in several significant scientific and industry conferences. The company focuses on developing a clinical pipeline of small molecule therapies, particularly targeting chronic inflammatory and autoimmune diseases. Through these events, Immunic aims to engage with experts and share valuable insights from its latest research.
Highlighting Scientific Contributions at Digestive Disease Week
From May 3-6, Immunic will present two abstracts at the Digestive Disease Week (DDW) conference. Held in San Diego, California, this event is known for gathering leading researchers in the field of gastroenterology. The first abstract, titled IMU-856 vs. Placebo Efficacy Effects in Celiac Disease Patients Are Independent of Q-MARSH Scale at Baseline, will be showcased to highlight findings from Immunic's phase 1/1b clinical trial of IMU-856, an oral modulator targeting SIRT6 for celiac disease management.
Details of the First Presentation
- Abstract ID: 4216653
- Poster Number: Tu1329
- Presenting Author: Dr. Indira Pichetto Olanda
- Session: Enteropathies — Celiac, Gluten Related and Environmental
- Session Date: Tuesday, May 6
- Session Time: 12:30 – 1:30 PM PDT
Another abstract titled Influence of Gut Epithelial Condition on the Pharmacokinetic Properties of IMU-856, an Oral Regulator of Barrier Function for the Treatment of Celiac Disease will also be presented, showcasing the promising results of this innovative treatment.
Details of the Second Presentation
- Abstract ID: 4219364
- Poster Number: Tu1344
- Presenting Author: Dr. Jacques Arend
- Session Date: Tuesday, May 6
- Session Time: 12:30 – 1:30 PM PDT
Insights on Clinical Trial Supply at Clinical Trial Supply Forum
Following DDW, Immunic will participate in the Clinical Trial Supply Forum 2025 from May 13-15. This forum, which will take place in Brussels, Belgium, offers a platform for discussing challenges within the clinical trial supply chain. Kimi Oanh Le, Immunic’s Head of Clinical Trial Supply, will present a case study that delves into the supply chain challenges faced in the Middle East and North Africa (MENA) region.
Case Study Highlights
- Case Study Title: Immunic Therapeutics Supply Chain Challenges Working Across MENA
- Presentation Date: Wednesday, May 14
- Time: 10:40 AM CEST (4:40 AM EDT)
Annual Meeting of the Consortium of Multiple Sclerosis Centers
Excitement doesn’t stop there. From May 28-31, Immunic's team will attend the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025 in Phoenix, Arizona. The meeting comprises the latest advancements in multiple sclerosis treatments, and attendees can visit Immunic at booth #911. A poster presentation will spotlight the preclinical data of vidofludimus calcium (IMU-838), an innovative asset targeting neuroprotection in multiple sclerosis.
Poster Presentation Details
- Poster Title: In Preclinical Models, Vidofludimus Calcium Exhibits Potential Neuroprotective Effects in Multiple Sclerosis by Modulating Nurr1
- Presenting Author: Dr. Amelie Schreieck
- Abstract ID: 10271
- Poster Board Label: NDM01
- Date: Thursday, May 29
- Time: 5:00 – 7:00 PM MST
About Immunic, Inc.
Immunic, Inc. is dedicated to the advancement of new therapies for chronic inflammatory and autoimmune diseases. Their lead product, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for treating relapsing multiple sclerosis, which shows promise in previous phases. This innovative product acts on the nuclear receptor related 1 (Nurr1) and exhibits both neuroprotective and anti-inflammatory effects.
Frequently Asked Questions
What events is Immunic participating in May?
Immunic is participating in Digestive Disease Week, Clinical Trial Supply Forum, and CMSC Annual Meeting.
What is IMU-856?
IMU-856 is an oral modulator targeting SIRT6, aimed at treating celiac disease and improving intestinal barrier function.
Who will present at the Clinical Trial Supply Forum?
Kimi Oanh Le, Immunic’s Head of Clinical Trial Supply, will present insights into supply chain challenges in the MENA region.
Where can I find presentations from the conferences?
All presentations will be available on Immunic's official website in the 'Events and Presentations' section.
What is Immunic’s focus in drug development?
Immunic focuses on small molecule therapies for chronic inflammatory and autoimmune diseases, particularly in areas such as multiple sclerosis.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.